Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Asceneuron.

    Client Virtual Booth

    ASCENEURON

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Asceneuron
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    EPFL Innovation Park Bâtiment B CH-1015 Lausanne
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.asceneuron.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/asceneuron-sa/
    Twitter
    Twitter
    https://twitter.com/asceneuron_sa

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)

    Details:

    Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.


    Lead Product(s): ASN90

    Therapeutic Area: Neurology Product Name: ASN90

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Ferrer Internacional

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies

    Details:

    The grant will fund a preclinical proof-of-concept study to assess the disease-modifying properties of Asceneuron’s OGA inhibitor ASN51 in a preclinical model of inherited PD.


    Lead Product(s): ASN51

    Therapeutic Area: Neurology Product Name: ASN51

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson’s Research

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Funding May 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer's and Parkinson's Disease Models

    Details:

    Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's model.


    Lead Product(s): ASN90

    Therapeutic Area: Neurology Product Name: ASN90

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences

    Details:

    ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathic disease, progressive supranuclear palsy (PSP), and was granted Orphan Drug Designation by the US FDA for the treatment of Progressive Supranuclear Palsy (PSP).


    Lead Product(s): ASN120290

    Therapeutic Area: Neurology Product Name: ASN120290

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search